Physician profile
Puneet Tandon
NPI 1760443832
$2,621.00
in general payments reported to CMS, 2019-2025
16 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2021: $225 · 2022: $469 · 2023: $640 · 2024: $610 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $430.72 | 2021-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $351.02 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $332.79 | 2021-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $300.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $249.76 | 2022-2025 | Jesduvroq, Benlysta |
| Ardelyx, INC. | $142.81 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Baxter Healthcare | $140.45 | 2023 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.44 | 2024 | Jardiance |
| Novo Nordisk INC | $122.29 | 2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $116.09 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $108.35 | 2023-2024 | Bard Urinary Drainage Bag |
| Kowa Pharmaceuticals America, INC. | $70.31 | 2019 | |
| Alnylam Pharmaceuticals INC. | $41.92 | 2021 | |
| Vifor Pharma, INC. | $37.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.89 | 2024-2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $20.42 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.